DILI Prediction | InSphero

Discover the predictive power of 3D liver models engineered for pharma

Drug-induced liver injury (DILI) continues to be a major source of clinical attrition, precautionary warnings, and post-market withdrawal of drugs. 3D InSight™ Human Liver Microtissues demonstrate enhanced liver phenotype, metabolic activity, and stability in culture not attainable with conventional two-dimensional hepatic models. They are a proven 3D liver co-culture model of hepatocytes and Kupffer cells, engineered for predicting drug induced liver injury, providing greater confidence in compound classification, lead prioritization, and reducing the risk of late-stage attrition.

  • Double the sensitivity in DILI prediction without sacrificing specificity using an organotypic, metabolically robust, long-lived spheroid model validated with a set of 110 clinically-defined DILI compounds
  • Leverage greater mechanistic accuracy using pooled multi-donor primary human hepatocyte (PHH) and Kupffer cell co-cultures, optimized for 14 day long-term in vitro DILI assessment
  • Ensure reproducibility and continuity in longitudinal and multi-site studies with standardized, pre-qualified models available for delivery to your lab on a weekly basis

DILI Prediction Applications

Tier 1: Short-Term

(Max. 7 days)

Screen quickly with high specificity for potential DILI drugs

Tier 2: Long-Term

(14 days)

Ensure highest sensitivity for DILI drugs with long-term exposure

Translational Toxicity

Compare susceptibility of different pre-clinical species to hepatotoxicity

The mechanistically accurate, organotypic biology of 3D InSight™ Liver

Microtissues mirrors that of native liver tissue.

3D InSight™ Liver Microtissues capture responses other in vitro models miss.

Compounds with clinically defined DILI severity (1 severe, 2 high concern, 3 low concern) predicted [+] or missed [-] by 3D InSight™ Human Liver Microtissues and 2D PHH from the same donor lots.

A more predictive, pharma validated DILI model

Genentech and AstraZeneca put 3D InSight™ Human Liver Microtissues to the test against traditional PHH assays, using a set of 110 clinically-defined DILI compounds. The results speak for themselves.

Request Additional Resources

Brochure: Solutions for Toxicology

Request

Poster: Drug Safety Assessment with Liver Microtissues

Request

Brochure: Human Liver Microtissues

Request

Find out how you can detect and predict DILI

earlier in your testing workflow.

Get Started